Uric Acid, Hypertension, and Cardiovascular and Renal Complications

被引：54

作者：

Zoccali, Carmine ^{[1
,2
,3
,4
,5
]}

Mallamaci, Francesca ^{[1
,2
,3
]}

机构：

[1] Osped Riuniti Reggio Calabria, CNR Natl Res Council Italy, Clin Epidemiol & Physiopathol Renal Dis & Hyperte, I-89124 Reggio Di Calabria, Italy

[2] Osped Riuniti Reggio Calabria, Nephrol Hypertens & Renal Transplantat Unit, I-89124 Reggio Di Calabria, Italy

[3] Osped Riuniti Reggio Calabria, Renal & Transplantat Unit, I-89124 Reggio Di Calabria, Italy

[4] Osped Riuniti Reggio Calabria, I-89124 Reggio Di Calabria, Italy

[5] Osped Riuniti Reggio Calabria, CNR, I-89124 Reggio Di Calabria, Italy

来源：

CURRENT HYPERTENSION REPORTS | 2013年 / 15卷 / 06期

关键词：

Uric acid; Hypertension; Chronic kidney disease; CKD; End-stage renal disease; ESRD; Cardiovascular risk; Endothelial dysfunction; Inflammation; Atherosclerosis; Arteriolosclerosis; Nephrosclerosis; CORONARY-HEART-DISEASE; LEFT-VENTRICULAR MASS; MUSCLE-CELL-PROLIFERATION; CHRONIC-KIDNEY-DISEASE; HIGH-BLOOD-PRESSURE; ENDOTHELIAL DYSFUNCTION; RISK-FACTORS; GLOMERULAR HYPERTENSION; ATHEROSCLEROSIS RISK; GROWTH-FACTOR;

D O I：

10.1007/s11906-013-0391-y

中图分类号：

R6 [外科学];

学科分类号：

1002 ; 100210 ;

摘要：

Over the last decade, the biologic interference of uric acid with the cardiovascular (CV) system and the kidney has been intensively investigated, and several experimental studies in animal models and in vitro documented that hyperuricemia may trigger hypertension and incite endothelial dysfunction, vascular damage and renal disease. A substantial proportion of epidemiological studies are compatible with the hypothesis that hyperuricemia may be noxious to the CV system and the kidney as well. However, there are still no well-powered trials testing whether uric acid-lowering interventions may reduce BP or attenuate the risk for adverse CV and renal outcomes. Evidence still remains largely insufficient to recommend changes in the current policy of not prescribing uric acid-lowering drugs to individuals with asymptomatic hyperuricemia.

引用

页码：531 / 537

页数：7

共 73 条

[1] The Relationship between Serum Uric Acid and Spirometric Values in Participants in a Health Check: The Takahata Study [J].

Aida, Yasuko ;

Shibata, Yoko ;

Osaka, Daisuke ;

Abe, Shuichi ;

Inoue, Sumito ;

Fukuzaki, Koji ;

Tokairin, Yoshikane ;

Igarashi, Akira ;

Yamauchi, Keiko ;

Nemoto, Takako ;

Nunomiya, Keiko ;

Kishi, Hiroyuki ;

Sato, Masamichi ;

Watanabe, Tetsu ;

Konta, Tsuneo ;

Kawata, Sumio ;

Kato, Takeo ;

Kubota, Isao .

INTERNATIONAL JOURNAL OF MEDICAL SCIENCES, 2011, 8 (06) :470-478

[2] Childhood uric acid predicts adult blood pressure - The Bogalusa Heart Study [J].

Alper, AB ;

Chen, W ;

Yau, L ;

Srinivasan, SR ;

Berenson, GS ;

Hamm, LL .

HYPERTENSION, 2005, 45 (01) :34-38

[3] Serum uric acid and cardiovascular disease: Recent developments, and where do they leave us? [J].

Baker, JF ;

Krishnan, E ;

Chen, L ;

Schumacher, HR .

AMERICAN JOURNAL OF MEDICINE, 2005, 118 (08) :816-826

[4] Association of Uric Acid With Change in Kidney Function in Healthy Normotensive Individuals [J].

Bellomo, Gianni ;

Venanzi, Sandro ;

Verdura, Claudio ;

Saronio, Paolo ;

Esposito, Antonella ;

Timio, Mario .

AMERICAN JOURNAL OF KIDNEY DISEASES, 2010, 56 (02) :264-272

[5] Uric acid is a risk factor for myocardial infarction and stroke - The Rotterdam Study [J].

Bos, Michiel J. ;

Koudstaal, Peter J. ;

Hofman, Albert ;

Witteman, Jacqueline C. M. ;

Breteler, Monique M. B. .

STROKE, 2006, 37 (06) :1503-1507

[6] Uric acid stimulates vascular smooth muscle cell proliferation and oxidative stress via the vascular renin-angiotensin system [J].

Corry, Dalila B. ;

Eslami, Pirooz ;

Yamamoto, Kei ;

Nyby, Michael D. ;

Makino, Hirofumi ;

Tuck, Michael L. .

JOURNAL OF HYPERTENSION, 2008, 26 (02) :269-275

[7] Serum uric acid and risk for cardiovascular disease and death: The Framingham Heart Study [J].

Culleton, BF ;

Larson, MG ;

Kannel, WB ;

Levy, D .

ANNALS OF INTERNAL MEDICINE, 1999, 131 (01) :7-+

[8] Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE):: a randomised trial against atenolol [J].

Dahlöf, B ;

Devereux, RB ;

Kjeldsen, SE ;

Julius, S ;

Beevers, G ;

de Faire, U ;

Fyhrquist, F ;

Ibsen, H ;

Kristiansson, K ;

Lederballe-Pedersen, O ;

Lindholm, LH ;

Nieminen, MS ;

Omvik, P ;

Oparil, S ;

Wedel, H .

LANCET, 2002, 359 (9311) :995-1003

[9] Ten-year incidence of elevated blood pressure and its predictors: The CARDIA Study [J].

Dyer, AR ;

Liu, K ;

Walsh, M ;

Kiefe, C ;

Jacobs, DR ;

Bild, DE .

JOURNAL OF HUMAN HYPERTENSION, 1999, 13 (01) :13-21

[10] Uric acid and cardiovascular risk [J].

Feig, Daniel I. ;

Kang, Duk-Hee ;

Johnson, Richard J. .

NEW ENGLAND JOURNAL OF MEDICINE, 2008, 359 (17) :1811-1821

← 1 2 3 4 5 6 7 8 →